SmithKline Beecham's Tagamet HB adds heartburn prevention claim.
This article was originally published in The Tan Sheet
Executive Summary
TAGAMET HB HEARTBURN PREVENTION CLAIM APPROVED BY FDA on Nov. 15. With the approval, SmithKline Beecham gains a new indication for its OTC H2 antagonist, which was approved for the treatment of heartburn in June ("The Tan Sheet" June 26, pp. 1-4). Tagamet HB was introduced in mid-August.